Adverum Biotechnologies - Multiplikator forward rega marang pendapatan ADVM

Lambang korporat lan logo Adverum Biotechnologies (ADVM)

The stable management of Adverum Biotechnologies (ADVM) has established the foundation for the final stages of trials, which supports the issuer's forward P/S. The company aims to capture the ocular gene therapy niche through its Ixo-vec drug. The prospect of replacing frequent injections for AMD with a single shot makes the asset an attractive M&A target, and 90.80 becomes the new metric value determining the business's market valuation.

Adverum Biotechnologies Inc. - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ADVM (periode 21.05.2023 - 13.11.2025)

Rincian metrik lan analitis perusahaan Adverum Biotechnologies Inc. (ADVM)

Analisis kabeh metrik perusahaan:Adverum Biotechnologies, Inc. (ADVM)
Produk sing diprodhuksi Adverum Biotechnologies, Inc.

Forward P/S measures the market value of a business relative to its expected sales volume, allowing investors to assess the degree of optimism priced in between reporting periods. By analyzing the expected P/S multiple, one can evaluate the extent to which the market has priced the success of Adverum Biotechnologies (ADVM) gene therapy clinical expansion and the completion of Phase II/III trials into the company's current capitalization.